Table 4.
Patterns of top and selected classes and medications use
| All patients (N = 11,204) | Autoimmune conditions (N = 2,465) | |||
|---|---|---|---|---|
| Baseline n (%) |
Follow-up n (%) |
Baseline n (%) |
Follow-up n (%) |
|
| Percentage of patients with at least one prescription for most common classes of medications | ||||
| Adrenal cortical steroids | 6502 (58.0) | 6999 (62.5) | 1737 (70.4) | 1842 (74.7) |
| Analgesics | 6083 (54.3) | 5847 (52.2) | 1550 (62.8) | 1494 (60.6) |
| Bronchodilators | 5857 (52.3) | 6104 (54.5) | 1262 (51.2) | 1299 (52.7) |
| Antihyperlipidemic agents | 5620 (50.2) | 5644 (50.4) | 1053 (42.7) | 1085 (44.0) |
| Beta-adrenergic blocking agents | 4446 (39.7) | 4671 (41.7) | 809 (32.8) | 889 (36.0) |
| Proton pump inhibitors | 4438 (39.6) | 4831 (43.1) | 1143 (46.3) | 1223 (49.6) |
| Percentage of patients with at least one prescription for selected classes of medications | ||||
| Oral corticosteroids | 5135 (45.8) | 6,750 (60.2) | 1,448 (58.7) | 1,690 (68.5) |
| Non-biological DMARDs | 2596 (23.2) | 2,973 (26.5) | 1,070 (43.4) | 1,130 (45.8) |
| Immunomodulators | 485 (4.3) | 891 (7.9) | 320 (13.0) | 568 (23.0) |
| Biological DMARDs | 455 (4.1) | 551 (4.9) | 296 (12.0) | 335 (13.6) |
| Percentage of patients with at least one prescription for selected medications | ||||
| Adalimumab | 59 (0.5) | 53 (0.5) | 52 (2.1) | 46 (1.9) |
| Azathioprine | 218 (1.9) | 372 (3.3) | 151 (6.1) | 246 (10.0) |
| Cyclophosphamide | 20 (0.2) | 31 (0.3) | 9 (0.4) | 14 (0.6) |
| Etanercept | 46 (0.4) | 41 (0.4) | 42 (1.7) | 38 (1.5) |
| Intravenous immunoglobulin | 80 (0.7) | 126 (1.1) | 34 (1.4) | 45 (1.8) |
| Infliximab | 27 (0.2) | 18 (0.2) | 25 (1.0) | 16 (0.6) |
| Methotrexate | 372 (3.3) | 309 (2.8) | 314 (12.7) | 238 (9.6) |
| Mycophenolate mofetil | 244 (2.2) | 470 (4.2) | 170 (6.9) | 320 (13.0) |
| Rituximab | 35 (0.3) | 107 (1.0) | 22 (0.9) | 67 (2.7) |
| Tacrolimus | 84 (0.7) | 124 (1.1) | 23 (0.9) | 33 (1.3) |